" In addition to the potential to provide significant patient benefit and improved patient outcome, SFP is expected to reduce related healthcare costs considerably. Because SFP is delivered via dialysate, required supplies such as needles and syringes needed for current IV therapy are avoided and nursing time to deliver and manage IV iron is no longer needed. Furthermore, because SFP is designed to continously maintain iron balance, as opposed to IV iron which is dosed infrequently to replenish iron after Hgb has dropped below a certain threshold, ESA dose is expected to be significantly reduced, which should result in considerable savings to the dialysis provider.
In the U.S. approximately $680M per year is spent on IV iron for ESRD patients; and $1.5B globally."
If you happen to have the misfortune of being in the medical field in the U.S. with the recent transition to obamacare, you have probably noted a few changes. At this time if a patient with COPD, CHF, End Stage Renal Diseases (ESRD) or Diabetes returns to the hospital within 30 days of treatment for the same problem, the hospital is not reimbursed for the visit by Medicare/Medicaid.
Dialysis patients are in and out of the hospital on quite the regular basis and for the first time in our history we are now focused on; COST BASIS. In the past a patient, e.g Terri Schivo, who showed to be brain dead would have stayed on life support for decades but with the current shift we no longer allow such futile efforts on behalf of the tax payers. This is the future of medicine and saving money is just as important as saving lives.